Barclays raised the firm’s price target on Regeneron to $1,220 from $1,200 and keeps an Overweight rating on the shares post the Q2 report. The analyst says the Street shrugged off the modest HD Eylea miss, instead focusing on near-term COPD approval and second half of 2024 clinical catalysts.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron reports Q2 adjusted EPS $11.56, consensus $10.61
- Notable companies reporting before tomorrow’s open
- Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
- BioNTech’s BNT111 meets primary Phase 2 endpoint in advanced melanoma
- REGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?